Anavex Life Sciences Corp (AVXL)

[Steady_T]

The one thing I heard in the presentation that caught my attention was when Missling said that 2-73 works even further upstream than we thought it did.

That comment was with the slide about chromatin.

The further upstream in the disease processes that 2-73 intervenes, the wider the applicability of the drug. So it seems to me that ultimately 2-73 will be utilized in more indications than are presently being targeted. Probably indications that have not even been considered at this point.

Of course that does lead to 2-73 as a general tonic for aging. Which may be the largest market of all.

I also found interesting that slide that showed the dosages being stepped up in 10 mg increments to the ultimate targeted dose. I was not previously aware of that part of the protocol.